MX2010000721A - Polimeros anfifilicos de autoensamble como agentes anticancer. - Google Patents

Polimeros anfifilicos de autoensamble como agentes anticancer.

Info

Publication number
MX2010000721A
MX2010000721A MX2010000721A MX2010000721A MX2010000721A MX 2010000721 A MX2010000721 A MX 2010000721A MX 2010000721 A MX2010000721 A MX 2010000721A MX 2010000721 A MX2010000721 A MX 2010000721A MX 2010000721 A MX2010000721 A MX 2010000721A
Authority
MX
Mexico
Prior art keywords
amphifilic
self
polymers
anticancer agents
white
Prior art date
Application number
MX2010000721A
Other languages
English (en)
Other versions
MX341715B (es
Inventor
Jayant G Tatake
Anil R Diwan
Ann Louise Onton
Original Assignee
Allexcel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allexcel Inc filed Critical Allexcel Inc
Publication of MX2010000721A publication Critical patent/MX2010000721A/es
Publication of MX341715B publication Critical patent/MX341715B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención provee copolímeros biocompatibles anfifílicos que tienen una estructura hidrofílica y grupos hidrofóbicos pendientes. Los polímeros forman agregados moleculares en medios acuosos que tienen interiores hidrofóbicos dentro de los cuales se pueden solubilizar las drogas anticáncer. Los polímeros caracterizan opcionalmente ligandos fijados, ligandos de receptores y otros restos blanco que median la adherencia de los agregados portadores de la droga con las células cancerosas blanco.
MX2010000721A 2007-07-19 2007-07-19 Polímeros anfifílicos de autoensamblaje como agentes anticáncer. MX341715B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/073880 WO2009011702A1 (en) 2007-07-19 2007-07-19 Self-assembling amphiphilic polymers as anticancer agents

Publications (2)

Publication Number Publication Date
MX2010000721A true MX2010000721A (es) 2010-05-24
MX341715B MX341715B (es) 2016-08-23

Family

ID=40259892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000721A MX341715B (es) 2007-07-19 2007-07-19 Polímeros anfifílicos de autoensamblaje como agentes anticáncer.

Country Status (15)

Country Link
US (1) US9770442B2 (es)
EP (1) EP2167103B1 (es)
JP (1) JP5296787B2 (es)
KR (1) KR101470679B1 (es)
CN (1) CN101795695B (es)
AP (1) AP2941A (es)
AU (1) AU2007356525B2 (es)
BR (1) BRPI0721759B1 (es)
CA (1) CA2691002C (es)
EA (1) EA200901451A1 (es)
HK (1) HK1224232A1 (es)
IL (1) IL202182A (es)
MX (1) MX341715B (es)
NZ (1) NZ581210A (es)
WO (1) WO2009011702A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2009042825A2 (en) * 2007-09-27 2009-04-02 The University Of Akron Process of preparing functionalized polymers via enzymatic catalysis
WO2010138802A2 (en) * 2009-05-28 2010-12-02 Cornell University Compositions and their use for removing cholesterol
EP2438908A1 (en) 2010-10-11 2012-04-11 Vectum Pharma, S.L. Anchoring compositions for topical applications
MX356528B (es) 2011-05-11 2018-06-01 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
MX366404B (es) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
CN110023407B (zh) * 2016-09-20 2021-10-29 康奈尔大学 标记的聚(酯酰胺氨基甲酸酯)、由其形成的纳米粒子和其用途
WO2018175589A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified peptides and uses thereof for treating cancer
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods
US10618023B2 (en) 2017-10-18 2020-04-14 International Business Machines Corporation Formation of a janus microcapsule
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
CN108354902A (zh) * 2018-05-22 2018-08-03 杭州市肿瘤医院 一种阿帕替尼聚合物胶束及其制备方法
CN111514293A (zh) * 2020-05-03 2020-08-11 大连理工大学 近红外无重原子氟硼吡咯在光动力治疗转移瘤及上转换中的应用
EP4359542A1 (en) * 2021-06-23 2024-05-01 The Johns Hopkins University Methods and materials for treating cancer
WO2022271183A1 (en) * 2021-06-25 2022-12-29 Allexcel Inc. Self-assembling amphphlic polymers as anti-covid-19 agents
KR102671525B1 (ko) * 2022-02-14 2024-05-31 강원대학교산학협력단 극성 양이온성 고분자, 비극성 음이온성 화합물 및 금나노입자를 포함하는 온도 및 산화 응답성 유효성분 전달체 및 이를 포함하는 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942243A (en) * 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
EP1063254A1 (de) * 1999-06-25 2000-12-27 Technische Uni München, Klinikum rechts der Isar, Inst. für Experiment. Onkoligie und Therapieforschung Copolymere für den Transport von Nukleinsäuren in die Zelle
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
GB0221942D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Drug delivery
US7316816B2 (en) * 2004-06-10 2008-01-08 Agency For Science Technology And Research Temperature and pH sensitive copolymers
CA2606270A1 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
KR101529318B1 (ko) * 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
AU2006336311B2 (en) * 2006-01-19 2013-01-24 Allexcel, Inc. Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers
NZ576948A (en) * 2007-01-22 2010-12-24 Allexcel Inc Self-assembling amphiphilic polymers as antiviral agents

Also Published As

Publication number Publication date
EA200901451A1 (ru) 2010-06-30
AU2007356525A1 (en) 2009-01-22
CN101795695B (zh) 2016-01-06
HK1146705A1 (zh) 2011-07-08
CN101795695A (zh) 2010-08-04
NZ581210A (en) 2012-04-27
EP2167103A4 (en) 2012-11-28
MX341715B (es) 2016-08-23
IL202182A (en) 2015-06-30
WO2009011702A1 (en) 2009-01-22
KR101470679B1 (ko) 2014-12-08
US9770442B2 (en) 2017-09-26
CA2691002A1 (en) 2009-01-22
HK1224232A1 (zh) 2017-08-18
AP2010005129A0 (en) 2010-02-28
AU2007356525B2 (en) 2014-07-17
EP2167103A1 (en) 2010-03-31
AP2941A (en) 2014-07-31
EP2167103B1 (en) 2017-03-01
JP5296787B2 (ja) 2013-09-25
BRPI0721759A2 (pt) 2014-02-11
JP2010533710A (ja) 2010-10-28
IL202182A0 (en) 2010-06-16
KR20100038384A (ko) 2010-04-14
CA2691002C (en) 2016-05-10
BRPI0721759B1 (pt) 2022-04-12
US20100239659A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
MX2010000721A (es) Polimeros anfifilicos de autoensamble como agentes anticancer.
WO2011079279A3 (en) Nanoconjugates and nanoconjugate formulations
CY1125495T1 (el) Φαρμακευτικη συνθεση αποτελουμενη αποτιβοζανιμπη
EP3988089A4 (en) LIPIDAN NOPARTICLES FOR IN VIVO DRUG DELIVERY AND ITS APPLICATIONS
EP2516504A4 (en) BIODEGRADABLE POLYMERS, COMPLEXES THEREOF FOR GENE THERAPY AND AGGREGATE EXTRACTION AND THE METHOD THEREOF
EP2626079A3 (en) Conjungated factor VIII molecules
CY1117587T1 (el) Αναστολεις κινασης τυροσινης bruton
CY1112292T1 (el) Χρηση του 2-6-(3-αμινο-πιπεριδιν-1-υλ)-3-μεθυλ-2,4-διοξο-3,4-διυδρο-2η-πυριδιν-1-υλμεθυλ-4-φθορο-βενζονιτριλιου για την αγωγη του διαβητη, του καρκινου, αυτοανοσων διαταραχων και της μολυνσεως hiv
EP3281956A3 (en) Human antibody drug conjugates against tissue factor
WO2015069773A8 (en) Devices and methods for continuous drug delivery via the mouth
BRPI0822026A2 (pt) Prepação farmacêutica ou nutracêutica revestida com liberação acentuada de substância ativa no cólon.
EP3549963A3 (en) High molecular weight zwitterion-containing polymers
WO2011057225A3 (en) Self-assembled particles from zwitterionic polymers and related methods
EP2346896A4 (en) ETOPOSID AND DOXORUBICIN CONJUGATES FOR ACTIVITY EXTRACTION
WO2010033240A3 (en) Carbohydrate-based drug delivery polymers and conjugates thereof
MX385823B (es) Conjugados de anticuerpo-farmaco hidrofilicos.
EP2559429A4 (en) SYSTEM FOR THE ADMINISTRATION OF ANTICREMENT WITH PH-SENSITIVE METAL NANOPARTICLES
WO2009148777A3 (en) Implantable drug delivery devices having alternating hydrophilic and amphiphilic polymer layers
EP2544701A4 (en) POLYMER CONJUGATES FOR DRUG DELIVERY AND METHOD FOR THE PRODUCTION AND USE THEREOF
MX375502B (es) Composiciones de nanoparticulas novedosas.
NO20083573L (no) Amfifile polymerer for opploseliggjoring og malrettet avgivelse av legemidler
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
AR095072A1 (es) Conjugados antibióticos
WO2014179615A3 (en) Biodegradable copolymers, forming and using same
EP3399963C0 (en) GEL COMPOSITIONS FOR TRANSDERMAL DELIVERY FOR MAXIMIZING DRUG CONCENTRATION IN THE STRATUM CORNEUM AND SERUM AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
FG Grant or registration